Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B

Part of paid clinical trials in Baltimore, Maryland.

Sponsor
University of Maryland, Baltimore
Study ID
NCT06154278
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Chronic Hepatitis B

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Imdusiran (AB-729) — DRUG
    60mg subcutaneously, every 8 weeks, for a total of 4 doses

Study Details

The goal of this clinical trial is to learn about the action of Imdusiran (AB-729) in the liver of people with chronic hepatitis B. The main questions it aims to answer are: * how well is it working in the liver * how does Imdusiran affect the hepatitis B virus Participants will receive injections of Imdusiran, one injection every 8 weeks, for a total of 4 doses. They will also undergo 2 liver biopsies: one with the first dose of Imdusiran, and the second 8 weeks after the last dose of Imdusiran.

Key Dates

Start date
Jul 25, 2024
Status verified
Sep 2025
Primary completion
Dec 1, 2026
Completion
Jul 1, 2027

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Imdusiran (AB-729)
    Participants receive subcutaneous injections of 60mg, one injection every 8 weeks for 4 doses.

Primary Outcome Measure

Intrahepatic concentration of Imdusiran (AB-729) [ Time Frame: During intervention (with first dose of Imdusiran) and after intervention (8 weeks after last dose of Imdusiran) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Institute of Human Virology, University of Maryland School of MedicineBaltimoreMaryland21201
Lisa Anderson, RN, BS
[email protected]
(410) 706-4069

Find similar trials in Baltimore, MD

By research site
Institute of Human Virology, University of Maryland School of Medicine· Baltimore, MD

Related Studies